Dr. Dara J. Lundon is the Director of Clinical Trials & Innovation at the Icahn School of Medicine at Mount Sinai Hospital. His area of expertise involves cancer biology, statistics, bioinformatics, and integrating artificial intelligence and machine learning methods to improve risk stratification in early and advanced prostate cancer.

Dr. Lundon hails from outside Mullingar in Co. Westmeath. He graduated from The School of Medicine at University College Dublin, where he was admitted as an Entrance Scholar for outstanding academic achievement. He undertook his residency in Ireland and subsequently completed his Ph.D. in Prostate Cancer Biology. Dr. Lundon undertook training at the NIH in Bethesda and a fellowship at New York University.

In recognition of his contributions to science and medicine, Dr. Lundon has received awards and accolades from academies and associations, including the European Association of Urology and the Royal Academy of Medicine.

He was awarded European Young Investigator of the Year, and has authored numerous peer-reviewed publications, book chapters, and a textbook and has been an invited speaker at international medical and scientific meetings.  He has served as a medical advisor to government and non-profit initiatives and is an academic mentor to physicians and students in health sciences. Dr. Lundon is actively involved in the area of translational clinical trials for therapeutics and devices and is also working to develop novel in-vitro diagnostics. ♦